Tradestie Institutional Equity Comparison Engine

RGNX vs GLUE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

GLUE Overall Edge

GLUE Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Monte Rosa Therapeutics, Inc. Common Stock (GLUE) driven by superior Valuation, Options & Structure while RGNX counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus GLUE at 10.0x Forward P/E and -214.5% operating margin (+325.8% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against GLUE sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GLUE
RGNX N/M vs GLUE 10.0x Fwd P/E
Growth & Margin Winner RGNX
Op Margin -120.4% vs -214.5% ยท YoY -69.2% vs +325.8%
Momentum & Technical Winner RGNX
1Y -35.8% vs -36.4% ยท 52W Pos 19% vs 1%
Options & Structure Winner GLUE
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (16th %ile IV)
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
1M Return +7.87%
1Y Return -35.82%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.11
-2.77% 1D
Market Cap $795.5M
1M Return -6.47%
1Y Return -36.38%
Forward P/E 10.0x
Unified AI Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RGNX -35.82% GLUE -36.38% Spread: +0.56 pp (RGNX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RGNX Revenue GLUE Revenue RGNX Op. Margin GLUE Op. Margin Margin Edge
FY2018 $220M N/A 40.3% N/A RGNX
FY2019 $40M N/A -422.9% N/A RGNX
FY2020 $150M N/A -77.1% N/A RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M N/A -297.1% N/A RGNX
FY2024 $80M $80M -280.0% -107.3% GLUE
FY2025 $170M $120M -94.6% -43.8% GLUE

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RGNX (4) vs GLUE (6)
Institutional Metric RGNX GLUE Criterion Row Winner
Market Capitalization Scale $500.9M $795.5M Larger Scale GLUE
Trailing P/E Ratio Valuation N/M 10.0x Lower Multiple GLUE
Forward P/E Ratio Valuation N/M 10.0x Lower Multiple GLUE
Revenue Growth (YoY) Growth -69.2% +325.8% Higher Growth GLUE
Operating Margin (TTM) Profitability -120.4% -214.5% Higher Margin RGNX
Net Profit Margin Profitability -113.9% -186.2% Higher Margin RGNX
Return on Equity (ROE) Capital Efficiency -113.2% -35.3% Higher ROE GLUE
52-Week Range Position Momentum 19% ($5โ€“$16) 1% ($9โ€“$26) Stronger Trend RGNX
Beta / 30D Volatility Risk Regime 1.81ฮฒ ยท 76% Vol 0.94ฮฒ ยท 53% Vol Lower Realized Risk GLUE
Unified Institutional Score Composite Signal 45.3 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite RGNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RGNX vs GLUE Buy Guide
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GLUE BREAKDOWN
85d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live GLUE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RGNX nor GLUE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.